House Bill 1527 introduces new protections for 340B entities in Florida, which are healthcare organizations that provide discounted medications to eligible patients. The bill establishes definitions for "340B drug" and "340B entity" and prohibits drug manufacturers from interfering with the acquisition and delivery of 340B drugs to pharmacies associated with these entities. It also imposes restrictions on health insurance issuers and pharmacy benefit managers, preventing them from reimbursing 340B entities at lower rates than non-340B entities and from imposing different terms or conditions based on 340B status. Any violations of these prohibitions are classified as deceptive and unfair trade practices under the Florida Deceptive and Unfair Trade Practices Act, which carries penalties for offenders.

Additionally, the bill specifies that HMOs and PBMs cannot require the submission of ingredient costs or pricing data for 340B drugs, nor can they exclude 340B organizations from their networks solely based on their participation in the 340B program. However, it clarifies that these provisions do not apply to the Medicaid program regarding reimbursement for covered outpatient drugs. The act is set to take effect on July 1, 2025, and aims to ensure equitable treatment for 340B entities within Florida's healthcare system while safeguarding their ability to provide affordable medications to patients.